| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
This compound is not a drug and does not have a pharmacological target. It is a synthetic intermediate used in organic chemistry. Its role is to serve as a chiral building block for constructing nucleoside analogues that target viral polymerases or cellular kinases.
|
|---|---|
| ln Vitro |
No direct in vitro activity as this is a synthetic intermediate. However, the final L-nucleoside products derived from this intermediate exhibit antiviral activity against hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV by inhibiting viral reverse transcriptase or RNA-dependent RNA polymerase.
|
| ln Vivo |
No direct in vivo activity for the intermediate itself. The L-nucleosides synthesized from it, such as L-deoxythymidine, have shown in vivo efficacy in animal models of viral infection, reducing viral load and improving liver histology without significant mitochondrial toxicity.
|
| Enzyme Assay |
Not applicable. For related L-nucleosides, standard assays involve measuring inhibition of viral polymerases using purified enzyme, template/primer, and radiolabeled nucleotides. The compound is added at various concentrations, and incorporated radioactivity is quantified by filter binding.
|
| Cell Assay |
Not applicable for this intermediate. For derived L-nucleosides, cellular assays use HBV-infected HepG2.2.15 cells or HCV replicon cells. Cells are treated with the compound for several days, and viral DNA/RNA is quantified by real-time PCR or Southern blot.
|
| Animal Protocol |
Not applicable for this intermediate. For L-nucleosides, in vivo studies use HBV-transgenic mice or woodchuck hepatitis virus models. The compound is administered orally or intraperitoneally, and serum viral DNA levels are monitored by PCR over 2-4 weeks.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not relevant for this synthetic intermediate. For L-nucleoside drugs, they typically have good oral bioavailability, are converted intracellularly to active triphosphates, and have half-lives of several hours in plasma.
|
| Toxicity/Toxicokinetics |
The intermediate is a chemical reagent and is handled with standard laboratory precautions. It is not intended for in vivo use. The L-nucleoside products have improved toxicity profiles compared to D-nucleosides, showing reduced mitochondrial toxicity and lower risk of lactic acidosis.
|
| References | |
| Additional Infomation |
This compound is solely a research chemical for organic synthesis. It has no clinical trials or approved status. It is commonly used in the preparation of L-configured nucleoside analogues, which are of interest for antiviral drug development due to their resistance to host nucleoside metabolizing enzymes.
|
| Molecular Formula |
C9H16O5
|
|---|---|
| Molecular Weight |
204.22
|
| Exact Mass |
204.099
|
| CAS # |
20672-63-3
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
-0.4
|
| SMILES |
CC1(O[C@H]2[C@@H](O[C@@H]([C@H]2O1)OC)CO)C
|
| InChi Key |
DXBHDBLZPXQALN-XAMCCFCMSA-N
|
| InChi Code |
InChI=1S/C9H16O5/c1-9(2)13-6-5(4-10)12-8(11-3)7(6)14-9/h5-8,10H,4H2,1-3H3/t5-,6-,7-,8-/m0/s1
|
| Chemical Name |
[(3aS,4S,6S,6aS)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]methanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (489.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8967 mL | 24.4834 mL | 48.9668 mL | |
| 5 mM | 0.9793 mL | 4.8967 mL | 9.7934 mL | |
| 10 mM | 0.4897 mL | 2.4483 mL | 4.8967 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
